Screener
Sionna Therapeutics SION Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | — | (86) |
| Purchases of marketable securities | (25,327) | (171,595) |
| Maturities of marketable securities | 50,147 | 30,487 |
| Net cash provided by (used in) investing activities | 24,820 | (141,194) |
| Cash flows from financing activities: | ||
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | — | 202,389 |
| Payment of deferred offering costs | (320) | — |
| Exercise of common stock options | 2,213 | — |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's investing cash flow?
- Sionna Therapeutics (SION) reported investing cash flow of $24.82M in Q1 2026.
- How has Sionna Therapeutics's investing cash flow changed year-over-year?
- Sionna Therapeutics's investing cash flow increased by 117.6% year-over-year, from -$141.19M to $24.82M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Sionna Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude